drugset
drugset / Trial / NCT00412412

CNF2024 (BIIB021) HER2- (QD) HER2+ (BIW w/Herceptin) PK/PD Study

NCT00412412 ↗

Phase 1 Completed 34 enrolled Biogen
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to study the drug CNF2024 as a single agent or in combination with trastuzumab in patients with advanced breast cancer and to: * find the highest dose of the drug CNF2024 as a single agent or in combination with trastuzumab that can be given safely * measure levels of CNF2024 as a single agent or in combination with trastuzumab in blood * determine if CNF2024 as a single agent or in combination with trastuzumab can stop breast cancer cells from growing

Timeline

Start
2007-12
Primary completion
2011-04
Completion
2011-04

Drugs

EvaluationDrugModalityDoseRoute
Subject BIIB021 Small molecule — Oral
Background Trastuzumab Monoclonal antibody — Intravenous

Indications

breast cancer